司帕生坦在IgA肾病gddY小鼠模型中优于氯沙坦
该研究在自发性IgA肾病gddY小鼠模型中比较了双重内皮素血管紧张素受体拮抗剂司帕生坦与单选择性血管紧张素II 1型受体拮抗剂氯沙坦的肾脏保护作用。在降压程度相似的剂量下,司帕生坦更快速且更显著地降低白蛋白肌酐比值,并更大程度延缓肾损伤进展。
要点
- 司帕生坦较氯沙坦更快速、更显著降低gddY小鼠白蛋白肌酐比值。
- 治疗4周白蛋白肌酐比值下降与16周时肾小球硬化和足细胞保护相关。
- 司帕生坦延缓肾损伤进展的程度大于氯沙坦。
核心结论
- 在gddY小鼠IgA肾病模型中,司帕生坦较氯沙坦更快速、更显著降低白蛋白肌酐比值并更大程度延缓肾损伤进展。
- 结合PROTECT试验结果,本研究为司帕生坦相较单纯AT1R拮抗具有更优肾脏保护机制提供了新视角。
研究设计与样本
- 4周龄gddY小鼠随机给予对照饲料、含司帕生坦饲料或含氯沙坦饮水,至12或20周龄。
- 司帕生坦与氯沙坦所用剂量产生相似的降压效果。
主要发现
- 司帕生坦治疗组白蛋白肌酐比值下降较氯沙坦组更快速且幅度更大。
- 治疗4周时白蛋白肌酐比值较基线的下降与16周时司帕生坦对肾小球硬化的改善、足细胞及糖萼的保护相关。
- 12周龄gddY小鼠肾脏ET-1、内皮素A型受体、AT1R及促炎基因mRNA表达上调,司帕生坦与氯沙坦预防程度相当。
关键数值与推荐
- 司帕生坦与氯沙坦所用剂量产生相似的降压效果。
- 司帕生坦治疗4周的白蛋白肌酐比值下降与16周时肾小球硬化及足细胞、糖萼保护相关。
临床怎么用
- 该临床前证据提示,在IgA肾病中双重内皮素血管紧张素受体拮抗较单纯AT1R拮抗可能带来更快速且更强的降蛋白尿与肾脏保护作用。
- 结果为司帕生坦在IgA肾病中的肾脏保护机制提供补充,但临床决策仍需结合PROTECT等临床试验证据。
局限性
- 本研究为gddY小鼠临床前模型,结论外推至IgA肾病患者需谨慎。
- 原文未报告样本量、具体剂量、P值及置信区间等详细统计信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The mechanism leading to the development of immunoglobulin A nephropathy (IgAN) remains to be completely understood. Endothelin-1 (ET-1) as well as angiotensin II (AngII) promote glomerular injury, tubulointerstitial inflammation and fibrosis leading to chronic kidney disease. Sparsentan, a dual endothelin angiotensin receptor antagonist, recently received accelerated approval in the USA for the reduction of proteinuria in adults with IgAN at high risk of disease progression. To elucidate the mechanisms by which sparsentan is efficacious in IgAN, we examined the effect of treatment in gddY mice, a spontaneous IgAN mouse model, versus the monoselective angiotensin II type 1 receptor (AT1R) antagonist, losartan, on the development of renal injury at doses resulting in similar blood pressure lowering. METHODS: Four-week-old gddY mice were given control chow, chow containing sparsentan or drinking water containing losartan until 12 or 20 weeks old. RESULTS: Remarkably, the albumin:creatine ratio (ACR) was attenuated more rapidly and to a greater extent in mice treated with sparsentan than those treated with losartan. The decrease in ACR from baseline after 4 weeks of treatment correlated with beneficial effects of sparsentan on glomerulosclerosis and protection of podocytes and glycocalyx after 16 weeks of treatment across treatment groups; thus, sparsentan treatment delayed development of renal injury to a greater extent than losartan. Expression of mRNA for ET-1, endothelin type A receptor and AT1R and proinflammatory genes was upregulated in 12-week-old gddY mice and was prevented by sparsentan and losartan to a comparable extent. CONCLUSIONS: The results of this study, and in light of the results of the phase 3 PROTECT trial, provide a novel perspective and understanding of the mechanisms by which sparsentan has a beneficial renoprotective effect against IgAN compared with AT1R antagonism alone.
引用
- Nagasawa H, Ueda S, Suzuki H, et al. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy. Nephrol Dial Transplant. 2024. PMID: 38271614. doi:10.1093/ndt/gfae021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。